Oncology News | pharmaphorum

News

AstraZeneca and Daiichi Sankyo logos next to Datroway box

Datroway filed for TNBC in EU after data delay

Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.

News

MSD claims two national priority vouchers; report

The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

Enhertu moves into frontline breast cancer treatment

Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.

News

J&J claims FDA's latest national priority voucher

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

Datroway filed for TNBC in EU after data delay

MSD claims two national priority vouchers; report

As year-end nears, pharma groups plump up their pipelines

Padcev/Keytruda scores again in early bladder cancer

Enhertu moves into frontline breast cancer treatment

J&J claims FDA's latest national priority voucher

Lilly points to long-lasting weight loss with orforglipron

How to meet your physicians where they are online

News

Editor's Picks